We are pleased to announce that Forbion, through our Forbion Growth Opportunities Fund II, has participated in the $150 million Series D financing of CatalYm GmbH. Forbion co-led the oversubscribed round via our Forbion Growth Opportunities Fund II (“Forbion Growth”) and new investors, Canaan Partners and Bioqube Ventures, along with Omega Funds and Gilde Healthcare Partners. CatalYm, a pioneer in developing new cancer treatments, was founded in 2016 by Forbion and BGV (BioGeneration Ventures) Ventures (BGV). The proceeds from this financing will support the expansion of CatalYm’s lead asset, visugromab, into earlier lines of treatment for select solid tumor indications. Visugromab has already demonstrated significant anti-tumor activity in combination with checkpoint inhibitor treatment. We are excited to continue supporting CatalYm in its mission to develop innovative cancer therapies. Click on the following link to learn more: https://lnkd.in/eSKy2mTu #financing #seriesD #lifesciences #biotech Jasper Bos Rogier Rooswinkel
Over ons
Forbion was born out of ABN AMRO Capital Life Sciences in 2000. Six years later, we transitioned to Forbion Capital Partners. Today, to emphasize our value-add beyond merely providing capital, we are simply known as Forbion. For more than two decades, our investment team has built an impressive track record of sourcing, building and guiding life-sciences companies resulting in many breakthrough therapies and valuable exits. Forbion currently manages over €2.3 bn across ten funds. As of October 2022, Forbion holds 43 active portfolio companies bringing its investments to 95 companies to date with 46 employees. Forbion’s investors include the European Investment Fund (EIF), notably through its European Recovery Programme (ERP), LfA, the Dutch Venture Initiative (DVI) and AMUF facilities, and the Kreditanstalt für Wiederaufbau (KFW) through the ERP – Venture Capital Fondsfinanzierung facility.
- Website
-
http://www.forbion.com
Externe link voor Forbion
- Branche
- Durfkapitaal en privévermogen
- Bedrijfsgrootte
- 11 - 50 medewerkers
- Hoofdkantoor
- Naarden
- Type
- Partnerschap
- Opgericht
- 2006
- Specialismen
- Developing novel drugs, Medical devices, life sciences, Health care, Therapeutics, Bioscience en Investment
Locaties
-
Primair
Gooimeer 2-35
Naarden, 1411 DC, NL
-
Maximilianstrasse 36
Munich, Bavaria 80539, DE
Medewerkers van Forbion
-
Robbert van de Griendt
-
Jasper Bos
General Partner at Forbion
-
Yigal Pinto
Head of Experimental Cardiology and Clinical Cardiologist at University of Amsterdam, Medical Director at ARMGO Pharma and CMO at Phlox Therapeutics,…
-
Machteld Groeneveld, LLM EMBA
Legal Counsel & Compliance Officer bij Forbion
Updates
-
Forbion portfolio company VectorY Therapeutics, a biotech company developing innovative vectorized antibody therapies for the treatment of neurodegenerative diseases, announces the appointment of Adam Rosenberg as the new Chair of the Board. Boston-based Mr Rosenberg brings over 20 years of experience in building and leading life sciences companies, primarily in the neuroscience space. He replaces Dr Carlo Incerti who is stepping down from the company’s board. The appointment comes at a pivotal time for VectorY as the company advances towards clinical development with a pipeline of strongly differentiated vectorized antibody treatments for neurodegenerative disorders. Click on the following link to read more: https://lnkd.in/eGy_BJa6 #lifesciences #biotech #appointment #clinicaldevelopment Wouter Joustra Dr. Dmitrij Hristodorov Vanessa Carle
-
Forbion is pleased to announce that we have led a $170 million in Series B funding for Beacon Therapeutics. We were joined by TCGX, and Advent Life Sciences, together with initial investments from Syncona Limited and Oxford Science Enterprises. The funds will support the clinical development of Beacon’s AGTC-501 for X-Linked Retinitis Pigmentosa and Phase 1/2 trials for their Dry Age-related Macular Degeneration program. Dr. Dmitrij Hristodorov and Wouter Joustra, General Partners at Forbion, will join Beacon Therapeutics’ Board of Directors, with Dominic Schmidt joining as a Board Observer. See the following link for more details: https://lnkd.in/ef6mD-B4 #Forbion #LifeSciences #Biotech #Ophthalmology #clincialdevelopment #seriesB #financing Mathias Vinther Anne Marije van Harten
-
Forbion is pleased to announce that Josh Brumm, formerly CEO of Dyne Therapeutics, has joined our team as General Partner. Josh will be based in our new Boston office, supporting our long-standing activities in the US and Canadian markets. With his extensive experience in biotech leadership, Josh will focus on sourcing new opportunities across North America and Europe and supporting our existing portfolio companies. This enhances our ability to drive innovation in the life sciences sector and marks an important milestone in our growth. Click here to learn more: https://lnkd.in/ecCwZbqD #lifesciences #biotech #appointment
-
It has been less than a week since we announced the first close of our new BioEconomy Fund at Eur 75 million. Hear more about the fund and its goals in this Real Deals article by Silvia Iacovcich. Silvia spoke to General Partner Alexander Hoffmann and Partner Joy Faucher for the Real Deals "Fund in Focus" feature. Click on the following link to read the article: https://lnkd.in/gybcGuTU #media #forbion #news #sustainability #biotech
-
We are excited to announce the first close of Forbion BioEconomy Fund I at €75 million. This new fund, led by Alexander Hoffmann and Joy Faucher, focuses on biotech-enabled solutions in #Food, #Agriculture, #Materials, and #Environmental #Technologies. The Forbion BioEconomy Fund aims to transform industries reliant on non-renewable resources by investing in sustainable, scalable, and cost-effective alternatives. Our team is supported by industry veterans Feike Sijbesma, ex-CEO of DSM, Cees de Jong, Chairman of Novonesis, Onno van de Stolpe, ex-CEO of Galapagos, and Stefan Oschmann, ex-CEO of Merck KGaA as Advisors and Venture Partners. This fund is a strategic expansion, leveraging our biotech expertise to address pressing planetary challenges. Join us as we drive innovations that will help clean and feed the planet. Click on the following link to learn more: https://lnkd.in/eumrYSSF #VentureCapital #Biotech #Sustainability #Forbion #BioEconomy
-
We are delighted to announce that Forbion has been recognized as the Top Performing European VC Manager as part of Preqin's 2024 Awards. This acknowledgment reflects our commitment to excellence and the hard work of our entire team. A huge thank you to everyone at Team Forbion. #Forbion #VC #VentureCapital #PreqinAwards #TopPerforming #Recognition #TeamWork #Innovation #Excellence #lifesciences #biotech *Disclaimer: Preqin awards are compiled using public domain information and data reported to Preqin by the participants; they are not independently verified or assessed. Preqin cannot therefore guarantee the accuracy of the information provided. Details of Preqin's proprietary methodology can be found for private capital and for hedge funds.*
-
We are excited to announce that Marea Therapeutics has launched with $190 million in financing to develop a new generation of medicines for #cardiometabolic diseases. Marea's lead program, MAR001, is a first-in-class ANGPTL4 inhibitor currently in Phase 2 clinical development. This innovative treatment aims to address the untreated lipid and metabolic drivers of cardiovascular events in high-risk patients. Antoine Boulanger, PhD, will join Marea's Board of Directors. We look forward to seeing the progress Marea will make in the fight against cardiometabolic diseases. Melanie de Almeida Click on the following link to learn more: https://lnkd.in/ejRJfQdR #lifesciences #biotech #seriesB
-
We are thrilled to release Episode 4 of "The Biotech Pulse: A Forbion Podcast." Episode Title: The Role of Biotech as the ‘Discovery Engine’ for Pharma Special Guests: - Felix Lansing, PhD - Co-founder and CTO of Seamless Therapeutics - Albert Seymour - CEO of Seamless Therapeutics Join us as our General Partner Dr. Dmitrij Hristodorov dives deep into the pivotal role of biotech in driving pharmaceutical innovation, especially in high-risk areas of R&D. In This Episode: - Explore how Seamless Therapeutics leverages recombinases for more targeted and efficient gene editing. - Understand the journey from a biotech startup to a global company. - Gather insights into the biotech-pharma ecosystem and its future. Do not miss this insightful conversation about the cutting-edge developments in gene therapy and the transformative potential of biotech in pharma! #BiotechPulse #Podcast #Forbion #Biotech #Pharma #GeneEditing #GeneTherapy #Recombinases #Innovation #CTO #CEO #StartupJourney #PharmaEcosystem #lifesciences Click on the following link to listen now https://lnkd.in/epg95hwJ
-
Qur heartfelt congratulations to Forbion Operating Partner Professor John Kastelein, on achieving an exceptional milestone in his academic career. This remarkable achievement places Professor Kastelein among the top 1,000 scientists globally in terms of research impact. At Forbion we are privileged to benefit from his expertise. Congratulations once again, Professor Kastelein on this well-deserved recognition! #Forbion #KOL #scientist #lifesciences #biotech #research #expert
We’re excited to congratulate our Chief Scientific Officer, Prof. John Kastelein, on achieving an h-index of 163, meaning he has published 163 articles that have been cited at least 163 times, amassing more than 118,000 total citations. The score places Prof. Kastelein among the top 1,000 scientists worldwide in terms of research impact.